Flexible Flat-Rate Plans
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
DrugPatentWatch Database Preview
EPIVIR-HBV Drug Profile
« Back to Dashboard
This drug has ninety-two patent family members in forty-eight countries.
The generic ingredient in EPIVIR-HBV is lamivudine. There are twenty-six drug master file entries for this compound. Twenty suppliers are listed for this compound. There are fifty-eight tentative approvals for this compound. Additional details are available on the lamivudine profile page.
Summary for Tradename: EPIVIR-HBV
| Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 2 |
| Suppliers / Packagers: see list | 3 |
| Drug Prices: : | see details |
Pharmacology for Tradename: EPIVIR-HBV
Clinical Trials for: EPIVIR-HBV
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Glaxosmithkline | EPIVIR-HBV | lamivudine | TABLET;ORAL | 021003-001 | Dec 8, 1998 | RX | Yes | 5,905,082*PED | Nov 18, 2016 | Y | |||||||||||||||||||
Glaxosmithkline | EPIVIR-HBV | lamivudine | SOLUTION;ORAL | 021004-001 | Dec 8, 1998 | RX | Yes | 6,004,968*PED | Sep 20, 2018 | Y | |||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Expired Patents for Tradename: EPIVIR-HBV
These historical archives are available as an add-on to one-year subscriptions.
See the Signup Form for more information.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Glaxosmithkline | EPIVIR-HBV | lamivudine | TABLET;ORAL | 021003-001 | Dec 8, 1998 | 5,047,407*PED | <disabled> | ||||||||||||||||||||||
Glaxosmithkline | EPIVIR-HBV | lamivudine | SOLUTION;ORAL | 021004-001 | Dec 8, 1998 | RE39155*PED | <disabled> | ||||||||||||||||||||||
Glaxosmithkline | EPIVIR-HBV | lamivudine | SOLUTION;ORAL | 021004-001 | Dec 8, 1998 | 7,119,202*PED | <disabled> | ||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Paragraph IV activity for: EPIVIR-HBV
| Drugname | Dosage | Strength | RLD | Submissiondate |
|---|---|---|---|---|
| lamivudine | Tablets | 100 mg | Epivir-HBV | 10/31/2007 |
International Patent Family for Tradename: EPIVIR-HBV
| Country | Document Number | Estimated Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hungary | 225600 | <disabled in preview> | |||||||||||||||||||||||||||
| Bulgaria | 64690 | <disabled in preview> | |||||||||||||||||||||||||||
| Portugal | 517145 | <disabled in preview> | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
Supplementary Protection Certificates for Tradename: EPIVIR-HBV
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 80018 | Netherlands | <disabled> | PRODUCT NAME: LAMIVUDINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN ZIDOVUDINE; REGISTRATION NO/DATE: EU/1/98/058/001-002 19980318 | ||||||||||||||||||||||||||
| C/GB98/019 | United Kingdom | <disabled> | PRODUCT NAME: A COMBINATION COMPRISING LAMIVUDINE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND ZIDOVUDINE; REGISTERED: UK EU/1/98/058/001 19980318; UK EU/1/98/058/002 19980318 | ||||||||||||||||||||||||||
| C0020 | Belgium | <disabled> | PRODUCT NAME: LAMIVUDINE/ZIDOVUDINE; REGISTRATION NO/DATE: EU/1/98/058/001 19980318 | ||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
« Back to Dashboard
For more information try a trial or see the database preview and plans and pricing
How are People Using DrugPatentWatch?
For Information on historical patent expiration of small molecules by formulation
— Life science strategy consulting, USA
For information on drug expiration / generic availability
— Pharmacist, USA
Better understanding of company drug patent expirations for investing purposes
— Analyst, USA
To identify business opportunities and check patent rights
— Managing director pharmaceutical company, Morocco
To study patents on drugs in selected therapeutic areas
— Pharmaceutical process development, India
To do IP due diligence for investment decisions
— Investment manager, South Korea
drugs and pharmaceutical products patents expiration details
— Marketing consultant, USA
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639
